Evoke Pharma, Inc.
EVOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $5 | $3 | $2 |
| % Growth | 97.8% | 106.5% | 55% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $10 | $5 | $2 | $1 |
| % Margin | 96.5% | 96.1% | 85.2% | 79.7% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15 | $12 | $10 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15 | $12 | $10 | $9 |
| Operating Income | -$5 | -$7 | -$8 | -$8 |
| % Margin | -50.8% | -143.4% | -310.4% | -503.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$5 | -$8 | -$8 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$8 | -$8 | -$9 |
| % Margin | -52.2% | -150.4% | -327.8% | -527.7% |
| EPS | -2.81 | -27.97 | -31.16 | -40.4 |
| % Growth | 90% | 10.2% | 22.9% | – |
| EPS Diluted | -2.81 | -27.97 | -31.16 | -40.4 |
| Weighted Avg Shares Out | 2 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $5 | $0 | $0 | $0 |
| EBITDA | $0 | -$7 | -$8 | -$8 |
| % Margin | 3.4% | -138.1% | -307.9% | -496.8% |